BEOVU (brolucizumab-vfrm) Patient Assistance Program
Don’t let the high cost of brand specialty intravitreal anti-VEGF therapy disrupt your treatment. We help eligible patients access Beovu (brolucizumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Beovu (brolucizumab) is FDA-approved for neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). It is a humanized single-chain antibody fragment (scFv) anti-VEGF given as intravitreal injection — designed for extended dosing intervals up to every 12 weeks.
- Without assistance, Beovu costs commonly run approximately $1,800–$2,200 per injection (per eye, per dose).
- Through AffordMyPrescriptions, qualifying patients can access Beovu for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of Beovu in the U.S. as of 2026. Beovu use has been somewhat limited by post-marketing reports of intraocular inflammation, retinal vasculitis, and retinal vascular occlusion — a concerning safety signal compared with other anti-VEGFs. Other intravitreal options include Lucentis (with biosimilars Byooviz/Cimerli), Eylea/Eylea HD, Vabysmo (dual VEGF/Ang2), and off-label compounded bevacizumab (much cheaper).
What Is Beovu Prescription Assistance Program?
The Beovu Prescription Assistance Program is a manufacturer-sponsored initiative that provides Beovu at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for retinal disease patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, retinal-specialist coordination, prior-authorization documentation, injection logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing injection-coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Beovu costs roughly $1,800–$2,200 per injection. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$2,100/dose | Save ~$2,030/dose |
| CVS Pharmacy | ~$2,200/dose | Save ~$2,130/dose |
| Walmart | ~$1,900/dose | Save ~$1,830/dose |
| Costco | ~$1,850/dose | Save ~$1,780/dose |
Specialty Pharmacy | ~$1,950/dose | Save ~$1,880/dose |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Beovu Prescription Program?
The Patient Assistance Program is free to apply for and provides Beovu at no medication cost if approved. Our $69.95/month service covers full advocacy. With multiple alternative anti-VEGF options available — and Beovu’s safety signal causing many retinal specialists to prefer alternatives — we’ll help your specialist determine the best path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Beovu:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
- Still $1,800–$2,200 per injection per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Beovu assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Beovu Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Beovu :
Beovu (brolucizumab) is an intravitreal anti-VEGF therapy used for wet AMD and DME. It is a small humanized single-chain antibody fragment (scFv) designed for greater intraocular concentration and the potential for extended dosing intervals — up to every 12 weeks in some patients after loading.
How Beovu Works:
Brolucizumab is a small antibody fragment designed to block VEGF-A, a protein that drives abnormal blood vessel growth and fluid leakage in retinal diseases like wet AMD. Its compact size allows for higher concentrations in the eye, which theoretically enables the medication to last longer than other treatments. While it was approved for infrequent dosing every 12 weeks, its use has been limited due to safety concerns. Specifically, post-marketing reports have identified higher rates of internal eye inflammation and vascular issues compared to similar therapies.
Form and use:
Beovu is administered as a 6 mg intravitreal injection performed by a retinal specialist during a brief office visit. Treatment typically begins with a loading phase of three to five monthly injections, followed by maintenance doses every 8 to 12 weeks depending on the specific condition. While the procedure only takes a few seconds, patients may experience mild discomfort or see floaters afterward. Continuous monitoring by a specialist is necessary to adjust the schedule based on how the disease responds.
Generic availability:
As of 2026, there are no biosimilar versions of Beovu available in the United States. Patients have access to several other anti-VEGF options, including ranibizumab and aflibercept, both of which now have lower-cost biosimilars on the market. Additionally, off-label compounded bevacizumab remains a dramatically cheaper alternative for many. Due to safety signals regarding inflammation and vasculitis, many specialists have transitioned to using these other established or newer extended-dosing medications.
Warnings:
Beovu carries significant warnings for retinal vasculitis and vascular occlusion, which require immediate discontinuation of the drug if they occur. It is associated with higher rates of intraocular inflammation, such as uveitis, and carries risks for rare but serious complications like endophthalmitis or retinal detachment. Other potential concerns include transient or sustained increases in eye pressure and a general class warning for arterial thromboembolic events. Patients should be monitored closely for any signs of hypersensitivity or vision changes following an injection.
FAQ (Frequently Asked Questions)
How Much Does Beovu Cost Without Insurance?
Beovu costs approximately $1,800–$2,200 per injection (per eye, per dose). Through AffordMyPrescriptions, qualifying patients receive Beovu at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Do Some Retinal Specialists Prefer Alternatives To Beovu?
Post-marketing surveillance identified intraocular inflammation, retinal vasculitis, and retinal vascular occlusion as adverse events at higher rates than other anti-VEGFs (Lucentis, Eylea, Vabysmo). These can cause severe vision loss. Many retinal specialists now prefer Eylea HD or Vabysmo for extended-interval anti-VEGF therapy, reserving Beovu for select situations. Discuss with your retinal specialist whether Beovu is the right choice for you.
How Often Will I Need Injections?
For wet AMD: monthly for 3 loading doses, then individualized based on disease activity — many patients can extend to every 8 or 12 weeks if disease is controlled. For DME: every 6 weeks for 5 doses, then every 8–12 weeks. Imaging (OCT) at each visit guides the dosing interval.
What Should I Watch For After Injection?
Watch for: severe eye pain (could indicate endophthalmitis — call your specialist immediately), severe vision changes or vision loss (could indicate retinal detachment, vasculitis, or vascular occlusion — emergency evaluation), increased eye redness with floaters and flashes, persistent eye pain. Mild post-injection irritation, redness, and floaters are common and typically resolve within hours to days.
Are There Cheaper Alternatives I Should Consider?
Yes. Off-label compounded bevacizumab (~$50–$100 per dose) is dramatically cheaper and is the most widely used anti-VEGF for wet AMD in the U.S. — with similar effectiveness to ranibizumab in head-to-head trials. Ranibizumab biosimilars (Byooviz, Cimerli) are also less expensive than Beovu. Eylea HD and Vabysmo offer extended dosing intervals like Beovu but with more favorable safety profiles in many specialists’ experience.
Can I Get Beovu Through The PAP If I Have Medicare?
If denied, we explore alternatives — switching to Eylea or Eylea HD (with its own PAP), Vabysmo, a ranibizumab biosimilar, or off-label bevacizumab (much cheaper), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Macular Degeneration Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
What If My Application Is Denied?
If denied, we explore alternatives — switching to a different anti-CGRP antibody with its own PAP (Aimovig, Emgality, Vyepti), trying an oral CGRP receptor antagonist (Qulipta, Nurtec ODT), trying generic preventives (beta-blockers, topiramate, amitriptyline) which may be sufficient, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the American Migraine Foundation, National Headache Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Beovu, our team may be able to help you access assistance programs designed to make brand specialty intravitreal anti-VEGF therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.